A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
Launched by HOFFMANN-LA ROCHE · Aug 16, 2007
Trial Information
Current as of May 03, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, 18-80 years of age;
- • histological diagnosis of primary central nervous system lymphoma;
- • B-cell proliferation verified by positive staining for CD20;
- • \>=1 measurable lesion.
- Exclusion Criteria:
- • prior chemotherapy, other than corticosteroids, \>=6 weeks before and after diagnosis or surgery;
- • history of prior cranial irradiation;
- • evidence of plurisystemic non-Hodgkin's lymphoma;
- • other active malignant disease (other than basal cell or squamous cell cancer of skin,or cancer in situ of cervix;
- • uncontrolled active infection.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Greenfield Park, Quebec, Canada
Quebec City, Quebec, Canada
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials